Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of AST-120 to Prevent Progression of Moderate to Severe Chronic Kidney Disease
2005-004990-13Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing AST-120 + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Primary composite endpoint of CKD progression. Started Sep 2007; status: completed.
02
Drugs
activated charcoal
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-004990-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004990-13.